Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lucía Notario"'
Autor:
Lucía Notario, Marc Cucurull, Gabriela Cerdà, Carolina Sanz, Enric Carcereny, Ana Muñoz-Mármol, Ainhoa Hernández, Marta Domènech, Teresa Morán, Montse Sánchez-Céspedes, Marta Costa, Jose-Luis Mate, Anna Esteve, Maria Saigí
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who wer
Externí odkaz:
https://doaj.org/article/6460f628e9154bd29ea1ff2e9b47c256
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11403 (2023)
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of gastric cancers. The implementation of targeted therapy against HER2 as p
Externí odkaz:
https://doaj.org/article/c4273883658f4a7083f3fb2081e5498d
Autor:
Marc Cucurull, Lucia Notario, Montse Sanchez-Cespedes, Cinta Hierro, Anna Estival, Enric Carcereny, Maria Saigí
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered “undruggable” for decades, spec
Externí odkaz:
https://doaj.org/article/ffbe2d7461754e19b5b912b54bef0fbb
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 9, p 4712 (2021)
Since 2010, several treatment options have been available for men with metastatic castration-resistant prostate cancer (mCRPC), including immunotherapeutic agents, although the clinical benefit of these agents remains inconclusive in unselected mCRPC
Externí odkaz:
https://doaj.org/article/d7a50cd9899c47808cecab108032fecf